Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
27 results
- D1.524 - StingReady: a safe and alternative method for controlled sting challenge tests
- D1.515 - Occupational Exposure of Patients Allergic to Hymenoptera Venom
- D1.516 - Compliance with hymenoptera venom inmunotherapy (VIT)
- D1.517 - Adverse Reactions to Insect Venom Immunotherapy in a Reference Center
- D1.518 - Patient Phenotypes in Prolonged Immunotherapy for Hymenoptera Venom
- D1.519 - Safety of ultra-rush protocols in venom immunotherapy: a systematic review and meta-analysis of Portuguese data
- D1.520 - Immunological modulation during Apis mellifera venom immunotherapy
- D1.521 - Rarer occurrence of cancer and autoimmune diseases among older patients with life-threatening allergic reactions to insect venom
- D1.522 - Efficacy of hymenoptera venom immunotherapy in Portugal: a systematic review
- D1.523 - Clinical characterization of patients with Hymenoptera venom allergy undergoing venom immunotherapy stratified by basal serum tryptase
- D1.525 - Implementation of allergen-specific immunotherapy for insect allergy
D1.526 - Epidemiologic Characteristics of Hymenoptera Venom Allergic Patients from Two Different Environmental Areas
- D1.527 - Low tryptase and combined IgE biomarkers have limited predictive value in children with severe honeybee venom anaphylaxis
- D1.532 - Phenotypic and Functional Comparison of LAD2, HMC-1.2, and Primary Human Mast Cells
- D1.529 - Evaluating the Disease-Modifying Potential of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis: An Update on the Pivotal HARBOR Study
- D1.530 - Patient Experience of Most Burdensome Nonadvanced Systemic Mastocytosis Symptoms From the Pivotal Summit Trial of Bezuclastinib
- D1.531 - Avapritinib in Indolent Systemic Mastocytosis: Real-world Data from a Greek Case Series
- D1.533 - Systemic mastocytosis despite normal baseline tryptase: a diagnostic pitfall in recurrent life-threatening anaphylaxis
- D3.519 - Post-COVID-19 Reshaping of Molecular IgE Sensitization Profiles to Seasonal and Indoor Allergens
- D3.520 - Post-COVID Olfactory and Taste Dysfunction in Students at a South African Medical School
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download